Affiliation:
1. Huntington and Rare Diseases Unit, Fondazione IRCCS Casa Sollievo Della Sofferenza Hospital San Giovanni Rotondo Italy
2. Bioinformatics Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza" San Giovanni Rotondo Italy
3. Rare Neurological Diseases Centre (CMNR) Fondazione Italian League for Research on Huntington (LIRH) Rome Italy
4. Department of Biotechnological and Applied Clinical Sciences University of L'Aquila L'Aquila Italy
Abstract
AbstractBackgroundCognitive changes in Huntington's disease (HD) precede motor manifestations. ENROLL‐HD platform includes four cognitive measures of information processing speed (IPS). Our group is eager to seek clinical markers in the life stage that is as close as possible to the age of onset (ie, the so called prodromal HD phase) because this is the best time for therapeutic interventions.ObjectivesOur study aimed to test whether cognitive scores in prodromal ENROLL‐HD mutation carriers show the potential to predict the severity of motor and behavioral changes once HD became fully manifested.MethodsFrom the global ENROLL‐HD cohort of 21,343 participants, we first selected a premanifest Cohort#1 (ie, subjects with Total Motor Score (TMS) <10 and Diagnostic Confidence Level (DCL) <4, N = 1.222). From this cohort, we then focused on a prodromal Cohort#2 of subjects who were ascertained to phenoconvert into manifest HD at follow‐up visits (ie, subjects from 6 ≤ TMS≤9 and DCL <4 to TMS≥10 and DCL = 4, n = 206).ResultsThe main results of our study showed that low IPS before phenoconversion in Cohort#2 predicted the severity of motor and behavioral manifestations. By combining the four IPS cognitive measures (eg, the Categorical Verbal Fluency Test; Stroop Color Naming Test; Stroop Word Reading; Symbol Digit Modalities Test), we generated a Composite Cognition Score (CCS). The lower the CCS score the higher the TMS and the apathy scores in the same longitudinally followed‐up patients after phenoconversion.ConclusionsCCS might represent a clinical instrument to predict the prognosis of mutation carriers who are close to manifesting HD.